Macrophage folate receptor-targeted antiretroviral therapy facilitates drug entry, retention, antiretroviral activities and biodistribution for reduction of human immunodeficiency virus infections

Nanomedicine: Nanotechnology, Biology, and Medicine

Volumn 9, Issue 8, 2013, Pages 1263-1273

  Puligujja, Pavan ^a   McMillan, JoEllyn ^a   Kendrick, Lindsey ^a   Li, Tianyuzi ^a   Balkundi, Shantanu ^a   Smith, Nathan ^a   Veerubhotla, Ram S ^a   Edagwa, Benson J ^a   Kabanov, Alexander V ^b   Bronich, Tatiana ^b   Gendelman, Howard E ^a,b   Liu, Xin Ming ^a,b  

^a UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^b UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

Author keywords

ATV r; Folate; Human immunodeficiency virus; Macrophages; NanoART; Poloxamer 407; Targeted drug delivery

Indexed keywords

ATV/R; FOLATE; HUMAN IMMUNODEFICIENCY VIRUS; NANOART; POLOXAMER 407; TARGETED DRUG DELIVERY;

DISEASES; DRUG DELIVERY; PLASTIC COATINGS; POLYMERS; VIRUSES;

MACROPHAGES;

ATAZANAVIR; CELL RECEPTOR; FOLATE RECEPTOR; FOLIC ACID; NANOCOATING; POLOXAMER; POLYMER; RITONAVIR;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTIVIRAL ACTIVITY; ARTICLE; BRAIN; CELL VIABILITY; CELLULAR DISTRIBUTION; CONTROLLED STUDY; DISPERSION; DRUG BLOOD LEVEL; DRUG COATING; DRUG DELIVERY SYSTEM; DRUG DISTRIBUTION; DRUG FORMULATION; DRUG PENETRATION; DRUG RECEPTOR BINDING; DRUG RETENTION; DRUG TARGETING; DRUG TISSUE LEVEL; DRUG UPTAKE; ENDOSOME; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; KIDNEY; LIVER; LYMPH NODE; MACROPHAGE; MALE; MOUSE; MUSCLE; NANOFABRICATION; NANOTECHNOLOGY; NONHUMAN; PARTICLE SIZE; PHYSICAL CHEMISTRY; SPLEEN; VIRUS REPLICATION; ZETA POTENTIAL;

HUMAN IMMUNODEFICIENCY VIRUS; MUS;

3-(4,5-DIMETHYLTHIAZOL-2-YL)-2,5-DIPHENYLTETRAZOLIUM BROMIDE; ATAZANAVIR; ATV; ATV/R; BOVINE SERUM ALBUMIN; BSA; CHINESE HAMSTER OVARY; CHO; FA; FOLATE; FOLATE RECEPTOR; FOLIC ACID; FOLR; HUMAN IMMUNODEFICIENCY VIRUS; LAMP; LYSOSOMAL ASSOCIATED MEMBRANE PROTEIN; MACROPHAGES; MDM; MONOCYTE-DERIVED MACROPHAGES; MTT; NANOART; NANOFORMULATED ANTIRETROVIRAL THERAPEUTICS; PARAFORMALDEHYDE; PBS; PDI; PFA; PHOSPHATE BUFFERED SALINE; POLOXAMER 407; POLYDISPERSITY INDEX; RECEPTOR-MEDIATED ENDOCYTOSIS; REVERSE TRANSCRIPTASE; RITONAVIR; RITONAVIR-BOOSTED ATAZANAVIR; RME; RT; RTV; TARGETED DRUG DELIVERY;

ANIMALS; ANTI-HIV AGENTS; CELLS, CULTURED; DRUG DELIVERY SYSTEMS; FOLATE RECEPTORS, GPI-ANCHORED; FOLIC ACID; HIV INFECTIONS; HIV-1; HUMANS; MACROPHAGES; MALE; MICE; MICE, INBRED BALB C; OLIGOPEPTIDES; PYRIDINES; TISSUE DISTRIBUTION;

EID: 84886436130     PISSN: 15499634     EISSN: 15499642     Source Type: Journal    
DOI: 10.1016/j.nano.2013.05.003     Document Type: Article

References (37)

1. Este J.A., Cihlar T. Current status and challenges of antiretroviral research and therapy. Antiviral Res 2010, 85:25-33.
2. Rao K.S., Ghorpade A., Labhasetwar V. Targeting anti-HIV drugs to the CNS. Expert Opin Drug Deliv 2009, 6:771-784.
3. Fogarty L., Roter D., Larson S., Burke J., Gillespie J., Levy R. Patient adherence to HIV medication regimens: a review of published and abstract reports. Patient Educ Couns 2002, 46:93-108.
4. Chesney M. Adherence to HAART regimens. AIDS Patient Care STDS 2003, 17:169-177.
5. Volberding P.A., Deeks S.G. Antiretroviral therapy and management of HIV infection. Lancet 2010, 376:49-62.
6. Bartlett J.A., Shao J.F. Successes, challenges, and limitations of current antiretroviral therapy in low-income and middle-income countries. Lancet Infect Dis 2009, 9:637-649.
7. Blankson J.N., Persaud D., Siliciano R.F. The challenge of viral reservoirs in HIV-1 infection. Annu Rev Med 2002, 53:557-593.
8. Balkundi S., Nowacek A.S., Veerubhotla R.S., Chen H., Martinez-Skinner A., Roy U., Mosley R.L., Kanmogne G., Liu X., Kabanov A.V., Bronich T., McMillan J., Gendelman H.E. Comparative manufacture and cell-based delivery of antiretroviral nanoformulations. Int J Nanomedicine 2011, 6:3393-3404.
9. Nowacek A.S., McMillan J., Miller R., Anderson A., Rabinow B., Gendelman H.E. Nanoformulated antiretroviral drug combinations extend drug release and antiretroviral responses in HIV-1-infected macrophages: implications for neuroAIDS therapeutics. J Neuroimmune Pharmacol 2010, 5:592-601.
10. Nowacek A.S., Miller R.L., McMillan J., Kanmogne G., Kanmogne M., Mosley R.L., Ma Z., Graham S., Chaubal M., Werling J., Rabinow B., Dou H., Gendelman H.E. NanoART synthesis, characterization, uptake, release and toxicology for human monocyte-macrophage drug delivery. Nanomedicine (Lond) 2009, 4:903-917.
11. Dou H., Destache C.J., Morehead J.R., Mosley R.L., Boska M.D., Kingsley J., Gorantla S., Poluektova L., Nelson J.A., Chaubal M., Werling J., Kipp J., Rabinow B.E., Gendelman H.E. Development of a macrophage-based nanoparticle platform for antiretroviral drug delivery. Blood 2006, 108:2827-2835.
12. McMillan J., Batrakova E., Gendelman H.E. Cell delivery of therapeutic nanoparticles. Prog Mol Biol Transl Sci 2011, 104:563-601.
13. Batrakova E.V., Gendelman H.E., Kabanov A.V. Cell-mediated drug delivery. Expert Opin Drug Deliv 2011, 8:415-433.
14. Kabanov A.V., Gendelman H.E. Nanomedicine in the diagnosis and therapy of neurodegenerative disorders. Prog Polym Sci 2007, 32:1054-1082.
15. Dash P.K., Gendelman H.E., Roy U., Balkundi S., Alnouti Y., Mosley R.L., Gelbard H., McMillan J., Gorantla S., Poluektova L. Long-acting nanoART elicits potent antiretroviral and neuroprotective responses in HIV-1-infected humanized mice. AIDS 2012, 26:2135-2144.
16. Dou H., Grotepas C.B., McMillan J.M., Destache C.J., Chaubal M., Werling J., Kipp J., Rabinow B., Gendelman H.E. Macrophage delivery of nanoformulated antiretroviral drug to the brain in a murine model of neuroAIDS. J Immunol 2009, 183:661-669.
17. Nowacek A.S., Balkundi S., McMillan J., Roy U., Martinez-Skinner A., Mosley R.L., Kanmogne G., Kabanov A.V., Bronich T., Gendelman H.E. Analyses of nanoformulated antiretroviral drug charge, size, shape and content for uptake, drug release and antiviral activities in human monocyte-derived macrophages. J Control Rel 2011, 150:204-211.
18. Roy U., McMillan J., Alnouti Y., Gautum N., Smith N., Balkundi S., Dash P., Gorantla S., Martinez-Skinner A., Meza J., Kanmogne G., Swindells S., Cohen S.M., Mosley R.L., Poluektova L., Gendelman H.E. Pharmacodynamic and antiretroviral activities of combination nanoformulated antiretrovirals in HIV-1-infected human peripheral blood lymphocyte-reconstituted mice. J Infect Dis 2012, 206:1577-1588.
19. Kadiu I., Nowacek A., McMillan J., Gendelman H.E. Macrophage endocytic trafficking of antiretroviral nanoparticles. Nanomedicine (Lond) 2011, 6:975-994.
20. Kularatne S.A., Low P.S. Targeting of nanoparticles: folate receptor. Methods Mol Biol 2010, 624:249-265.
21. Lu J., Li Z., Zink J.I., Tamanoi F. In vivo tumor suppression efficacy of mesoporous silica nanoparticles-based drug-delivery system: enhanced efficacy by folate modification. Nanomedicine 2012, 8:212-220.
22. Nukolova N.V., Oberoi H.S., Cohen S.M., Kabanov A.V., Bronich T.K. Folate-decorated nanogels for targeted therapy of ovarian cancer. Biomaterials 2011, 32:5417-5426.
23. Wang X., Li J., Wang Y., Cho K.J., Kim G., Gjyrezi A., Koenig L., Giannakakou P., Shin H.J., Tighiouart M., Nie S., Chen Z.G., Shin D.M. HFT-T, a targeting nanoparticle, enhances specific delivery of paclitaxel to folate receptor-positive tumors. ACS Nano 2009, 3:3165-3174.
24. Xia W., Hilgenbrink A.R., Matteson E.L., Lockwood M.B., Cheng J.X., Low P.S. A functional folate receptor is induced during macrophage activation and can be used to target drugs to activated macrophages. Blood 2009, 113:438-446.
25. Gendelman H.E., Orenstein J.M., Martin M.A., Ferrua C., Mitra R., Phipps T., Wahl L.A., Lane H.C., Fauci A.S., Burke D.S., et al. Efficient isolation and propagation of human immunodeficiency virus on recombinant colony-stimulating factor 1-treated monocytes. J Exp Med 1988, 167:1428-1441.
26. Balkundi S., Nowacek A.S., Roy U., Martinez-Skinner A., McMillan J., Gendelman H.E. Methods development for blood borne macrophage carriage of nanoformulated antiretroviral drugs. J Vis Exp 2010, 46.
27. Feng Y., Shen J., Streaker E.D., Lockwood M., Zhu Z., Low P.S., Dimitrov D.S. A folate receptor beta-specific human monoclonal antibody recognizes activated macrophage of rheumatoid patients and mediates antibody-dependent cell-mediated cytotoxicity. Arthritis Res Ther 2011, 13:R59.
28. Kalter D.C., Nakamura M., Turpin J.A., Baca L.M., Hoover D.L., Dieffenbach C., Ralph P., Gendelman H.E., Meltzer M.S. Enhanced HIV replication in macrophage colony-stimulating factor-treated monocytes. J Immunol 1991, 146:298-306.
29. Huang J., Gautam N., Bathena S.P., Roy U., McMillan J., Gendelman H.E., Alnouti Y. UPLC-MS/MS quantification of nanoformulated ritonavir, indinavir, atazanavir, and efavirenz in mouse serum and tissues. J Chromatogr B Analyt Technol Biomed Life Sci 2011, 879:2332-2338.
30. Manders E., Verbeek F., Aten J. Measurement of co-localization of objects in dual colour confocal images. J Microsc 1993, 169:375-382.
31. Hattori Y., Sakaguchi M., Maitani Y. Folate-linked lipid-based nanoparticles deliver a NFkappaB decoy into activated murine macrophage-like RAW264.7 cells. Biol Pharm Bull 2006, 29:1516-1520.
32. Puig-Kroger A., Sierra-Filardi E., Dominguez-Soto A., Samaniego R., Corcuera M.T., Gomez-Aguado F., Ratnam M., Sanchez-Mateos P., Corbi A.L. Folate receptor beta is expressed by tumor-associated macrophages and constitutes a marker for M2 anti-inflammatory/regulatory macrophages. Cancer Res 2009, 69:9395-9403.
33. Kanmogne G.D., Singh S., Roy U., Liu X., McMillan J., Gorantla S., Balkundi S., Smith N., Alnouti Y., Gautam N., Zhou Y., Poluektova L., Kabanov A., Bronich T., Gendelman H.E. Mononuclear phagocyte intercellular crosstalk facilitates transmission of cell-targeted nanoformulated antiretroviral drugs to human brain endothelial cells. Int J Nanomedicine 2012, 7:2373-2388.
34. Mayor S., Rothberg K.G., Maxfield F.R. Sequestration of GPI-anchored proteins in caveolae triggered by cross-linking. Science 1994, 264:1948-1951.
35. Rothberg K.G., Ying Y.S., Kamen B.A., Anderson R.G. Cholesterol controls the clustering of the glycophospholipid-anchored membrane receptor for 5-methyltetrahydrofolate. J Cell Biol 1990, 111:2931-2938.
36. Wu M., Fan J., Gunning W., Ratnam M. Clustering of GPI-anchored folate receptor independent of both cross-linking and association with caveolin. J Membr Biol 1997, 159:137-147.
37. Turek J.J., Leamon C.P., Low P.S. Endocytosis of folate-protein conjugates: ultrastructural localization in KB cells. J Cell Sci 1993, 106(Pt 1):423-430.